Interleukin-27 Gene Delivery for Modifying Malignant Interactions Between Prostate Tumor and Bone
- 1 December 2013
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 24 (12), 970-981
- https://doi.org/10.1089/hum.2013.091
Abstract
We have examined the role of a novel cytokine, interleukin-27 (IL-27), in mediating interactions between prostate cancer and bone. IL-27 is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models, including prostate cancer. Prostate cancer is frequently associated with metastases to the bone, where the tumor induces a vicious cycle of communication with osteoblasts and osteoclasts to induce bone lesions, which are a significant cause of pain and skeletal-related events for patients, including a high fracture risk. We describe our findings in the effects of IL-27 gene delivery on prostate cancer cells, osteoblasts, and osteoclasts at different stages of differentiation. We applied the IL-27 gene delivery protocol in vivo utilizing sonoporation (sonodelivery) with the goal of treating and reducing the growth of prostate cancer at a bone metastatic site in vivo. We used a new model of immune-competent prostate adenocarcinoma and characterized the tumor growth reduction, gene expression, and effector cellular profiles. Our results suggest that IL-27 can be effective in reducing tumor growth, can help normalize bone structure, and can promote enhanced accumulation of effector cells in prostate tumors. These results are promising, because they are relevant to developing a novel IL-27-based strategy that can treat both the tumor and the bone, by using this simple and effective sonodelivery method for treating prostate tumor bone metastases.Keywords
This publication has 63 references indexed in Scilit:
- TMPRSS2–ERG-Mediated Feed-Forward Regulation of Wild-Type ERG in Human Prostate CancersCancer Research, 2011
- Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destructionBone, 2011
- Interleukin‐27 inhibits human osteoclastogenesis by abrogating RANKL‐mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signalingArthritis & Rheumatism, 2010
- Expression of cell cycle regulator cdk2ap1 suppresses tumor cell phenotype by non-cell-autonomous mechanismsOral Oncology, 2009
- Micro-computed tomography assessment of fracture healing: Relationships among callus structure, composition, and mechanical functionBone, 2008
- Histopathological Assessment of Prostate Cancer Bone Osteoblastic MetastasesJournal of Urology, 2008
- Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone depositionClinical & Experimental Metastasis, 2008
- Androgen deprivation therapy for prostate cancer: new concepts and concernsCurrent Opinion in Endocrinology, Diabetes and Obesity, 2007
- Advances in Preclinical Investigation of Prostate Cancer Gene TherapyMolecular Therapy, 2007
- Mechanisms of Bone MetastasisNew England Journal of Medicine, 2004